Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to improve cancer treatment options for patients. The companyÂ’s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates include Provenge, an active cellular immunotherapy that has completed two phase 3 trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation was formerly known as Activated Cell Therapy, Inc. The company was founded in 1992 and is headquartered in Seattle, Washington
$6.72 (04/06/09)
